Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
02:43:35 EDT Sat 27 Apr 2024
Enter Symbol
or Name
USA
CA



News for U:PLX from 2023-04-27 to 2024-04-26 - 21 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-03-14 06:50U:PLXNews ReleaseProtalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business Results
2024-03-07 06:50U:PLXNews ReleaseProtalix BioTherapeutics to Announce Fiscal Year 2023 Financial and Business Results on March 14, 2024
2024-02-23 06:50U:PLXNews ReleaseProtalix BioTherapeutics to Participate in the 2024 BIO CEO & Investor Conference
2023-12-26 06:50U:PLXNews ReleaseProtalix BioTherapeutics Issues 2024 Letter to Stockholders
2023-11-30 04:00U:PLXNews ReleaseLevicept Appoints Eliot Forster as CEO
2023-11-06 06:50U:PLXNews ReleaseProtalix BioTherapeutics Reports Third Quarter 2023 Financial and Business Results
2023-10-30 06:50U:PLXNews ReleaseProtalix BioTherapeutics to Announce Third Quarter 2023 Financial and Business Results on November 6, 2023
2023-10-09 06:50U:PLXNews ReleaseProtalix BioTherapeutics Issues Statement Regarding Security Situation in Israel
2023-09-12 06:50U:PLXNews ReleaseProtalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors
2023-09-06 06:50U:PLXNews ReleaseProtalix BioTherapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
2023-08-07 06:50U:PLXNews ReleaseProtalix BioTherapeutics Reports Second Quarter 2023 Financial and Business Results
2023-08-01 06:50U:PLXNews ReleaseProtalix BioTherapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference
2023-07-31 06:50U:PLXNews ReleaseProtalix BioTherapeutics to Announce Second Quarter 2023 Financial and Business Results on August 7, 2023
2023-06-08 06:50U:PLXNews ReleaseProtalix BioTherapeutics to Host In-Person KOL Breakfast following the Approval of Elfabrio ‚ ® in both the United States and the European Union for Adults with Fabry Disease
2023-05-30 06:50U:PLXNews ReleaseProtalix BioTherapeutics Issues Letter to Stockholders
2023-05-23 06:50U:PLXNews ReleaseProtalix BioTherapeutics set to join Russell 3000 ‚ ® Index
2023-05-18 06:50U:PLXNews ReleaseProtalix BioTherapeutics Announces $20 Million Milestone Payment from Chiesi Global Rare Diseases
2023-05-10 06:00U:PLXNews ReleaseChiesi Global Rare Diseases and Protalix BioTherapeutics Announce FDA Approval of ELFABRIO ‚ ® (pegunigalsidase alfa-iwxj) for the Treatment of Fabry Disease
2023-05-05 06:46U:PLXNews ReleaseChiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Authorization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease
2023-05-04 06:50U:PLXNews ReleaseProtalix BioTherapeutics Reports First Quarter 2023 Financial and Business Results
2023-04-27 06:50U:PLXNews ReleaseProtalix BioTherapeutics to Announce First Quarter 2023 Financial and Business Results on May 4, 2023